688036:SSEShenzhen Transsion Holding Co., Ltd. Class A Analysis
Data as of 2026-03-17 - not real-time
CN¥56.38
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Shenzhen Transsion is trading at 56.38 CNY, well below its 20‑day SMA of 57.57 and the 50‑day SMA of 61.63, confirming a short‑term bearish bias. The 30‑day volatility of 44.6% and a bearish trend direction underscore heightened price swings, while the MACD histogram is positive, hinting at a possible near‑term bounce off the support near 52.53. Valuation metrics are attractive – a trailing P/E of 17 versus an industry average of 34 and a price‑to‑sales below 1 suggest the stock is **undervalued** relative to peers. However, revenue has contracted by 7.9% and margins remain thin, raising concerns about sustainable profitability. The dividend yield of 4.02% appears generous, but a payout ratio above 115% signals that the dividend may not be maintainable. Strong cash reserves of 25.2 billion CNY and low systematic risk (beta ≈ 0.04) provide a cushion against market turbulence. Geographic exposure to Africa, South‑East Asia and Latin America adds growth potential but also **moderate geographic and currency risk**. Overall, the stock sits at a technical support level with increasing volume, offering a speculative upside if the bearish trend reverses.
Given the cheap valuation, solid balance sheet, and emerging‑market foothold, the medium‑ to long‑term outlook leans **bullish**, provided the company can arrest revenue decline and improve margins. Investors should be cautious of the unsustainable dividend and current earnings weakness, but the upside potential from a valuation rebound and cash‑driven strategic initiatives makes a **buy** stance reasonable for longer horizons.
Given the cheap valuation, solid balance sheet, and emerging‑market foothold, the medium‑ to long‑term outlook leans **bullish**, provided the company can arrest revenue decline and improve margins. Investors should be cautious of the unsustainable dividend and current earnings weakness, but the upside potential from a valuation rebound and cash‑driven strategic initiatives makes a **buy** stance reasonable for longer horizons.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price is near a technical support level with increasing volume
- Bearish SMA positioning and overall bearish trend
- High dividend yield but unsustainable payout ratio
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervalued valuation multiples relative to industry peers
- Forward EPS growth implying a forward P/E around 9.7
- Strong cash position to fund market expansion in emerging regions
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strategic presence in high‑growth emerging markets
- Potential for margin improvement as scale benefits accrue
- Low systematic risk (beta) and ample liquidity supporting stability
Key Metrics & Analysis
Financial Health
Revenue Growth-7.90%
Profit Margin3.94%
P/E Ratio17.1
ROE12.71%
Debt/Equity9.15
P/B Ratio3.2
Industry P/E34.2
Technical Analysis
TrendBearish
RSI43.1
SupportCN¥52.53
ResistanceCN¥61.68
MA 20CN¥57.57
MA 50CN¥61.63
MA 200CN¥73.63
MACDBullish
VolumeIncreasing
Fear & Greed Index79.45
Valuation
GradeUndervalued
TypeBlend
Dividend Yield4.02%
Risk Assessment
Beta0.04
Volatility44.63%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.